Skye Bioscience, Inc.
SKYE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001516551
In the last 90 days, Skye Bioscience, Inc. insiders filed 0 open-market purchases and 3 sales; 42 institutions reported holding it in 13F filings for Q2 2026, worth $11.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Skye Bioscience, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 1 insider, $444.6K in total
- Insiders trading
- 1
- Net value
- −$444.6K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Skye Bioscience, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schwab Andrew J. | Director, 10% Owner | 0Indirect | Sep 24, 2026 | 5 |
| Rocklage Scott M | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| Diekman John D | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| 5AM Ventures II LP | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| 5AM Co-Investors II LP | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| 5AM Partners II, LLC | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| Parmar Kush | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| 5AM Ventures VII, L.P. | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| 5AM Partners VII, LLC | 10% Owner | 0Indirect | Sep 24, 2026 | 3 |
| Dhillon Punit | Chief Executive Officer | 1,419,823 | Aug 7, 2026 | 3 |
| Jenkins Annalisa | Director | – | Apr 2, 2026 | 2 |
| Smith Karen L. | Director | – | Apr 2, 2026 | 2 |
| Grayson Paul A. | Director | 259,701 | Apr 2, 2026 | 2 |
| Twitty Christopher | Chief Scientific Officer | – | Apr 2, 2026 | 2 |
| Charych Deborah H. | Director | – | Apr 2, 2026 | 2 |
| Diep Tuan Tu | Chief Operating Officer | 82,259 | Apr 2, 2026 | 2 |
| Arsenault Kaitlyn Melanie | Chief Financial Officer | 167,522 | Feb 9, 2026 | 1 |
| Arora Puneet S. | Chief Medical Officer | – | Feb 9, 2026 | 1 |
| Dalesandro Margaret | Director | – | Mar 4, 2024 | 0 |
| Tyle Praveen | Director | – | Mar 4, 2024 | 0 |
| Ward Keith Wayne | Director | – | Mar 4, 2024 | 0 |
| Emerald Health Sciences Inc. | 10% Owner | 169,407,901 | Mar 17, 2023 | 0 |
| Rai Sukhwinder Singh | Director | 73,561Indirect | Jan 9, 2023 | 0 |
| Heppell James L | Director | – | Sep 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:31 PM ET | Sep 22-23 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −148.1K | $1.62 | −$239.6K | −100.0%0 after | 4 lotsDuplicate filing |
| Sep 24, 2026 (view filing)4:29 PM ET | Sep 22-23 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −148.1K | $1.62 | −$239.6K | −100.0%0 after | 4 lots |
| Sep 18, 2026 (view filing)6:39 PM ET | Sep 16 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −33.9K | $1.91 | −$64.7K | −85.8%5.62K after | 2 lotsDuplicate filing |
| Sep 18, 2026 (view filing)6:37 PM ET | Sep 16 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −33.9K | $1.91 | −$64.7K | −85.8%5.62K after | 2 lots |
| Aug 20, 2026 (view filing)5:59 PM ET | Aug 18-20 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −375.8K | $0.3733 | −$140.3K | −4.6%7.85M after | 9 lotsDuplicate filing |
| Aug 20, 2026 (view filing)5:57 PM ET | Aug 18-20 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −375.8K | $0.3733 | −$140.3K | −4.6%7.85M after | 9 lots |
| Aug 22, 2025 (view filing)7:05 PM ET | Aug 21-22 | 1 day | Rocklage Scott M and 7 others10% Owner | SSale | −231.4K | $3.46 | −$800.5K | −80.1%57.5K after | 4 lotsDuplicate filing |
| Aug 22, 2025 (view filing) | Aug 21-22 | 1 day | Schwab Andrew J.Director, 10% Owner | SSale | −231.4K | $3.46 | −$800.5K | −80.1%57.5K after | 4 lots |
| Feb 28, 2025 (view filing) | Nov 15-18, 2024 | 105 days | Arsenault Kaitlyn MelanieChief Financial Officer | SSale | −43.2K | $4.99 | −$215.8K | −20.5%167.5K after | Amended2 lots |
| Nov 20, 2024 (view filing) | Nov 15-18 | 5 daysLate | Diep Tuan TuChief Development Officer | SSale | −19.6K | $4.99 | −$97.7K | −19.2%82.3K after | 2 lots |
| Nov 19, 2024 (view filing) | Nov 15-18 | 4 days | Dhillon PunitChief Executive Officer | SSale | −82.9K | $4.99 | −$413.9K | −20.1%329.8K after | 2 lots |
| Nov 19, 2024 (view filing) | Nov 15-18 | 4 days | Grayson Paul A.Director | SSale | −86.6K | $4.99 | −$432.1K | −25.0%259.7K after | 2 lots |
| Sep 13, 2024 (view filing)6:54 PM ET | Sep 11-13 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −266.3K | $6.57 | −$1.75M | −80.1%66.3K after | 6 lotsDuplicate filing |
| Sep 13, 2024 (view filing) | Sep 11-13 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −266.3K | $6.57 | −$1.75M | −80.1%66.3K after | 6 lots |
| Mar 15, 2024 (view filing)4:15 PM ET | Mar 13 | 2 days | Rocklage Scott M and 7 others10% Owner | PPurchase | +450.0K | $10.00 | +$4.50M | +5.7%8.39M after | |
| Feb 2, 2024 (view filing)4:32 PM ET | Jan 31 | 2 days | Rocklage Scott M and 7 others10% Owner | PPurchase | +5.21M | $2.31 | +$12.0M | +190.2%7.94M after | |
| Aug 31, 2023 (view filing)11:26 AM ET | Aug 29 | 2 days | Dhillon PunitChief Executive Officer | PPurchase | +881.0K | $0.0187 | +$16.5K | +3.6%25.7M after | Amended |
| Mar 17, 2023 (view filing)2:52 PM ET | Feb 22 | 23 daysLate | Emerald Health Sciences Inc.10% Owner | PPurchase | −2.50M | $0.00 | $0 | –0 after | Derivative |